Generic Name and Formulations:
Imiglucerase 200 Units, 400 Units; per vial; pwd; for IV infusion after reconstitution.
Sanofi Genzyme Company
Indications for CEREZYME:
For long-term enzyme replacement therapy in patients with confirmed Type 1 Gaucher disease that results in one or more of the following conditions: 1) anemia; 2) thrombocytopenia; 3) bone disease; 4) hepatomegaly or splenomegaly.
Adults and Children:
<2yrs: not recommended. ≥2yrs: Give by IV infusion over 1–2 hours. Individualize. Initial dose range: 2.5 Units/kg 3 times a week to 60 Units/kg once every 2 weeks.
Monitor periodically for IgG antibody formation during the first year. Patients previously treated with Ceredase (alglucerase inj) who have developed antibody or hypersensitivity to Ceredase. Monitor for pulmonary hypertension, pneumonia. Pregnancy (Cat.C). Nursing mothers.
GI upset, abdominal pain, rash, pruritus, fatigue, headache, fever, dizziness, chills, backache, tachycardia, inj site reactions, hypersensitivity. Also children: dyspnea, flushing, coughing,
Endocrinology Advisor Articles
- Update on Vitamin D and Calcium Supplements for Reducing Fracture Risk
- AAP Shares List of 5 Unnecessary Pediatric Tests and Procedures
- Severe Hypoglycemia Associated With Increased Mortality Risk in T2D
- Efficacy of CGM in Preterm Infants of Mothers With Diabetes
- SSRIs and SNRIs Linked to Type 2 Diabetes in Children, Adolescents
- High Grip Strength Associated With Lower Risk for Diabetes-Related AEs
- Statin Use for CVD Prevention Increases Diabetes Risk in Overweight Patients
- Optimal Timing of Gastric Bypass and Cholecystectomy When Both Procedures Clinically Indicated
- Does Asthma Contribute to Infertility?
- Short-Term Probiotics Increase Weight Loss in Overweight, Obesity